Evidence map›Paper›PMID 10811855›Full record

Trial reportThe Journal of clinical investigation2000

Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.

B F McAdam, I A Mardini, A Habib, A Burke, J A Lawson, S Kapoor, G A FitzGerald

Registry-linked trialOpen access · bronzeAbstract readClinical TrialControlled Clinical Trial
In one paragraph

Trial report in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03869268 (The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin), which is not on this map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03869268 phase4completednot on this mapstarted 2019, after this paper: background citation

The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

TypeinterventionalSponsorSheffield Teaching Hospitals NHS Foundation TrustRan2019 to 2023Enrolled72ConditionsAcute Coronary SyndromeArmsAspirin, Ticagrelor
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 254 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

B F McAdamCenter for Experimental Therapeutics, Department of Anesthesia, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
I A Mardini
A Habib
A Burke
J A Lawson
S Kapoor
G A FitzGerald
University of Pennsylvania · US

Funding

ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
STRUCTURAL STUDIES OF PLATELET GPIIB/IIIA ACTIVATIONP50HL054500 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRASS, LAWRENCE F · 1996 to 2005
$13.1M
TRAINING IN ANESTHESIA RESEARCHT32GM007612 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DEUTSCHMAN, CLIFFORD SCOTT · 1985 to 2012
$2.0M
NCRR NIH HHS M01 RR000040NCRR NIH HHS MO 1RR00040NHLBI NIH HHS HL 54500NHLBI NIH HHS P50 HL054500NIGMS NIH HHS T32 GM007612NIGMS NIH HHS T32-GM07612
6 · The paper itself

Abstract

To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF(1alpha) (PGI-M) and 11-dehydro thromboxane B(2) (Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans.

Indexed as

AdultAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEicosanoidsFemaleHumansIbuprofenInflammationIn Vitro TechniquesIsoenzymesLipid PeroxidationLipopolysaccharidesAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEicosanoidsIbuprofenIsoenzymesLipopolysaccharidesMembrane ProteinsProstaglandin-Endoperoxide SynthasesProstaglandinsPTGS1 protein, humanPTGS2 protein, humanPyrazolesSulfonamides

Identifiers

PMID10811855
PMCPMC315469
OpenAlexW2044706016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.